Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Homophenylalanine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 known ✓ | P23219 | 1/20 | 0.62 |
| ▸ | ALPI | P09923 | 1/20 | 0.62 |
| ▸ | PKM | P14618 | 1/20 | 0.62 |
| ▸ | XIAP | P98170 | 1/20 | 0.62 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.62 |
| ▸ | GRIK1 | P39086 | 3/20 | 0.60 |
| ▸ | ERAP1 | Q9NZ08 | 3/20 | 0.55 |
| ▸ | ANPEP | P15144 | 2/20 | 0.55 |
| ▸ | ERAP2 | Q6P179 | 2/20 | 0.55 |
| ▸ | KIF11 | P52732 | 4/20 | 0.53 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.53 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.53 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.53 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.51 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.51 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.51 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.51 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.51 |
| ▸ | GRIK3 | Q13003 | 1/20 | 0.51 |
| ▸ | IDO1 | P14902 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Homophenylalanine SCHEMBL2305748 | 1.00 | ALPI (0.62) | ALPIPKMPTGS1XIAPSLC7A5 | |
| Homophenylalanine SCHEMBL1245414 | 1.00 | ALPI (0.62) | ALPIPKMPTGS1XIAPSLC7A5 | |
| Homophenylalanine SCHEMBL1078733 | 0.98 | ALPI (0.64) | ALPIPKMPTGS1XIAPSLC7A5 | |
| Homophenylalanine SCHEMBL130567 | 0.98 | ALPI (0.64) | ALPIPKMPTGS1XIAPSLC7A5 | |
| Homophenylalanine SCHEMBL44311 | 0.98 | ALPI (0.64) | ALPIPKMPTGS1XIAPSLC7A5 | |
| Homophenylalanine SCHEMBL44312 | 0.98 | ALPI (0.64) | ALPIPKMPTGS1XIAPSLC7A5 | |
| Homophenylalanine SCHEMBL28287974 | 0.96 | ALPI (0.62) | ALPIPKMPTGS1XIAPSLC7A5 | |
| Homophenylalanine SCHEMBL28594537 | 0.96 | ALPI (0.62) | ALPIPKMPTGS1XIAPSLC7A5 | |
| Homophenylalanine SCHEMBL28286602 | 0.96 | ALPI (0.62) | ALPIPKMPTGS1XIAPSLC7A5 | |
| Homophenylalanine SCHEMBL1318113 | 0.91 | ALPI (0.56) | ALPIPKMPTGS1XIAPSLC7A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101684071-B | Method for splitting DL-p-hydroxymandelic acid | SHANGHAI BAOSTEEL CHEMICAL CO | 2012-12-26 | — | — | CN | claimed |
| CN-101684071-A | Method for splitting DL-p-hydroxymandelic acid | SHANGHAI BAOSTEEL CHEMICAL CO | 2010-03-31 | — | — | CN | claimed |
| US-20250376443-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION (US) | 2025-12-11 | — | — | US | disclosed |
| US-20250368604-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION (US) | 2025-12-04 | — | — | US | disclosed |
| US-12486278-B2 | MASP-2 inhibitors and methods of use | OMEROS CORPORATION (US) | 2025-12-02 | — | — | US | disclosed |
| US-20250129020-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION (US) | 2025-04-24 | — | — | US | disclosed |
| CN-119350433-A | MASP-2 inhibitors and methods of use | 奥默罗斯公司 | 2025-01-24 | — | — | CN | disclosed |
| US-12195427-B2 | MASP-2 inhibitors and methods of use | OMEROS CORPORATION (US) | 2025-01-14 | — | — | US | disclosed |
| CN-112867706-B | MASP-2 inhibitors and methods of use | 奥默罗斯公司 | 2024-11-15 | — | — | CN | disclosed |
| CN-118373875-A | MASP-2 inhibitors and methods of use | 奥默罗斯公司 | 2024-07-23 | — | — | CN | disclosed |
| CN-118251383-A | Macrocyclic compounds as proteasome beta subunit type 5 inhibitors | 利德探索中心有限公司 | 2024-06-25 | — | — | CN | disclosed |
| CN-1098255-C | Novel substituted piperazine derivatives having tachyknin receptor antagonists activity | AVENTIS PHARMA INC (US) | 2003-01-08 | — | — | CN | disclosed |
| CN-1083429-C | Substituted alkyldiamine derivatives and their use as tachykinin antagonists | MERRELL PHARMA INC (US) | 2002-04-24 | — | — | CN | disclosed |
| CN-1325843-A | Synthesis of 2-(s)-amino-4-phenyl (substituted aryl) butanoic acid and its ester (hydrochloride) | CHENGDU ORGANIC CHEM INST (CN) | 2001-12-12 | — | — | CN | disclosed |
| CN-1181753-A | Novel substituted piperazine derivatives having tachyknin receptor antagonists activity | HOECHST MARION ROUSSEL INC (US) | 1998-05-13 | — | — | CN | disclosed |
| CN-1155883-A | Substituted alkyldiamine derivatives and their use as tachykinin antagonists | MERRELL PHARMA INC (US) | 1997-07-30 | — | — | CN | disclosed |
| EP-0373881-B1 | Process for preparing optically active 2-oxoimidazolidine derivatives | TANABE SEIYAKU CO (JP) | 1994-01-26 | — | — | EP | disclosed |
| US-5013845-A | Process for preparing optically active 2-oxoimidazolidine derivatives | TANABE SEIYAKU CO., LTD. (JP) | 1991-05-07 | — | — | US | disclosed |
| EP-0373881-A2 | Process for preparing optically active 2-oxoimidazolidine derivatives | TANABE SEIYAKU CO., LTD. (JP) | 1990-06-20 | — | — | EP | disclosed |
| US-4746648-A | HYPOTENSIVE, ANTIULCER | Sanofi, Institut National de la Recherche Medicale (FR) | 1988-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12486278-B2 | MASP-2 inhibitors and methods of use | MASP2, METAP2, SPINT2 | PTGS1 3949/4885ALPI 3952/4885PKM 4199/4885 |
| US-20250368604-A1 | MASP-2 INHIBITORS AND METHODS OF USE | MASP2, METAP2, SPINT2 | PTGS1 3961/4885ALPI 3918/4885PKM 4183/4885 |
| US-12195427-B2 | MASP-2 inhibitors and methods of use | MASP2, METAP2, SPINT2 | PTGS1 3961/4885ALPI 3918/4885PKM 4183/4885 |
| US-20250376443-A1 | MASP-2 INHIBITORS AND METHODS OF USE | MASP2, METAP2, SPINT2 | PTGS1 3985/4885ALPI 3940/4885PKM 4345/4885 |
| US-20250129020-A1 | MASP-2 INHIBITORS AND METHODS OF USE | MASP2, METAP2, SPINT2 | PTGS1 3961/4885ALPI 3918/4885PKM 4183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.